AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06407973
Drug: Latanoprost plus adjunctive glaucoma medication
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* Adjunctive topical glaucoma medication(s) as selected by the Investigator
Trial: NCT05560529
Drug: TAU
RxNorm normalized name: Tauvid
DrugBank: Flortaucipir F-18 (DB14914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving TAU (usual pharmacotherapy in BED) over 20 weeks
Trial: NCT06170489
Drug: Bendamustine or gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Investigator-Selected chemotherapy of EITHER bendamustine by IV infusion at a dose of 90 or 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose of 1000 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
Trial: NCT04962126
Drug: Obinutuzumab 25 MG/1 ML Intravenous Solution
RxNorm normalized name: Obinutuzumab 25 MG/1 ML Intravenous Solution
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 \& Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles.
Trial: NCT06161532
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.
Trial: NCT06161532
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.
Trial: NCT05103904
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05012631
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
Trial: NCT06784843
Drug: Dexmedetomidine as an adjuvant to local anesthesia for peribulbar block
RxNorm normalized name: Aldex AN
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
Trial: NCT06784843
Drug: Midazolam as an adjuvant to local anesthesia for peribulbar block
RxNorm normalized name: Aldex AN
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
Trial: NCT06206564
Drug: Artesunate ointment
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
Trial: NCT06143670
Drug: Stannous fluoride toothpaste
RxNorm normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.454% w/w SnF2
Trial: NCT06143670
Drug: Sodium fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.243% w/w Sodium fluoride
Trial: NCT06785974
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily 20mg atorvastatin.
Trial: NCT04699188
Drug: TNO155
RxNorm normalized name: SHP2 inhibitor TNO155
DrugBank: Batoprotafib (DB19137)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP2 inhibitor
Trial: NCT05922878
Drug: ALTO-300
RxNorm normalized name: Altoprev
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALTO-300 capsule QD
Trial: NCT06783816
Drug: chimeric antigen receptor gene modified T cells
RxNorm normalized name: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
Trial: NCT00189722
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06789848
Drug: Ligufalimab
RxNorm normalized name: Ligufalimab
DrugBank: Ligufalimab (DB17542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks
Trial: NCT06789848
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks
Trial: NCT05150795
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
Trial: NCT06087835
Drug: Zibotentan/Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
Trial: NCT06087835
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive dapagliflozin as per the arms they are randomized to
Trial: NCT06566833
Drug: Casein phosphopeptide amorphous calcium phosphate
RxNorm normalized name: caseins
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remineralizing agents that acts as a fluoride booster
Trial: NCT06566833
Drug: 5% sodium fluoride varnish
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remineralizing agent that is used as a gold standard for remineralization
Trial: NCT06592547
Drug: Intravenous metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous beta-blockers, recieved FDA approval
Trial: NCT05099172
Drug: BAY2927088_formulation A
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05776979
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by vein over about 75 minutes
Trial: NCT05776979
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT05446298
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
Trial: NCT04995484
Drug: Belzutifan
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 40 mg tablets given as a single oral 80 mg dose.
Trial: NCT05815173
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.
Trial: NCT05815173
Drug: Ladarixin
RxNorm normalized name: Ladarixin
DrugBank: Ladarixin (DB16212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles.
Trial: NCT06137170
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Follow clinical administration.
Trial: NCT05479812
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Investigation Product in combination with approved therapy
Trial: NCT04912258
Drug: Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
RxNorm normalized name: ketotifen fumarate 0.019 mg INTRAOCULAR drug-eluting contact lens [ACUVUE Theravision with Ketotifen]
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: preoperative chemoembolization with Irinotecan Drug-eluting Beads
Trial: NCT06305182
Drug: Metreleptin
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection.
Trial: NCT06305182
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
Trial: NCT05140525
Drug: Macitentan Tablets
RxNorm normalized name: Macitentan Tablets
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg oral once daily
Trial: NCT05140525
Drug: Riociguat
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg to 2.5mg oral three times daily
Trial: NCT05186818
Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
RxNorm normalized name: Aficamten
DrugBank: Aficamten (DB18490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten tablets were administered orally once daily.
Trial: NCT05186818
Drug: Placebo to match aficamten
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets were administered orally once daily.
Trial: NCT05757492
Drug: CHS-006 (anti-TIGIT)
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arm A participants will receive CHS-006 administered via IV Q3W.
Trial: NCT05757492
Drug: toripalimab (anti-PD-1)
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B participants will receive toripalimab administered via IV Q3W.
Trial: NCT06253520
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
Trial: NCT06253520
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Trial: NCT06558214
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.
Trial: NCT04659031
Drug: ABC008
RxNorm normalized name: Immunoglobulin G1, anti-(human killer cell lectin-like receptor subfamily G member 1) (human-Mus musculus monoclonal ABC008 γ1-chain), disulfide with human-Mus musculus monoclonal ABC008 κ-chain, dime
DrugBank: Ulviprubart (DB18281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC008
Trial: NCT06024096
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin is a lipid-lowering agent of the statin family that functions by blocking a rate-limiting enzyme, Hydroxymethylglutaryl-CoA (HMG-CoA) reductase, in lipid metabolism. This agent is commonly used for primary and secondary prevention of dyslipidemia. Participants will be asked to take Atorvastatin 80 mg daily at night, for 4 weeks prior to the vaccination, and continue the statin therapy for 4 weeks after vaccination.~The 80mg dose of atorvastatin allows for evaluation of the immunologic effects of statin medication with a short duration of therapy prior to vaccination.
Trial: NCT05220514
Drug: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Trial: NCT05136404
Drug: Selpercatinib
RxNorm normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT05114941
Drug: intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
Trial: NCT01236287
Drug: Voclosporin
RxNorm normalized name: Voclosporin
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive voclosporin capsules, twice daily
Trial: NCT06203821
Drug: NP137
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NP137 for the Treatment of Resectable Pancreatic Cancer
Trial: NCT06539741
Drug: OxyCODONE 5 mg Oral Tablet
RxNorm normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg by mouth every 6 hours as needed for pain
Trial: NCT04899115
Drug: VE303
RxNorm normalized name: VE303
DrugBank: VE303 (DB17794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of VE303 taken daily for 14 days.~The quantity of each strain is proportioned to assure a specific per-strain per-capsule titer. The 8 strains are blended together with a micro-crystalline cellulose flow agent and placed in enteric capsules.
Trial: NCT04899115
Drug: oral vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled subjects will receive 5 days of oral vancomycin 125 mg four times a day (q.i.d).
Trial: NCT06522373
Drug: MT-0169
RxNorm normalized name: MT-0169
DrugBank: MT-0169 (DB17430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by Vein (IV)
Trial: NCT05646862
Drug: Inavolisib
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
Trial: NCT05646862
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
Trial: NCT05646862
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
Trial: NCT04690673
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g oral paractamol
Trial: NCT06295770
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
Trial: NCT06369714
Drug: Concerta
RxNorm normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate Hydrochloride Extended-Release Tablets with the following specifications: 18mg dosage, oral administration, once a day for a duration of 8 weeks.
Trial: NCT04625647
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05199688
Drug: Satralizumab
RxNorm normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
Trial: NCT06332599
Drug: BQT
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, tetracycline 500 mg four times a day, and metronidazole 400 mg four times a day
Trial: NCT06190678
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06525740
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT06525740
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05141006
Drug: BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection into the bladder
Trial: NCT05141006
Drug: Placebo for BOTOX
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection into the bladder
Trial: NCT05632159
Drug: Mg sulphate
RxNorm normalized name: MG 217 Psoriasis
DrugBank: Glyceryl 1-oleate (DB13171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation. With extra administration of intraoperative Magnesium sulphate 30 mg /kg as loading dose over 10 min then 10 mg /kg/ has maintenance dose
Trial: NCT05026593
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.
Trial: NCT05026593
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.
Trial: NCT05026593
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
Trial: NCT05026593
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .
Trial: NCT02080767
Drug: Tecovirimat
RxNorm normalized name: Tecovirimat
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
Trial: NCT05417646
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose, 25 mg, two hours before clamp
Trial: NCT05704361
Drug: RO7121932 IV - SAD
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 1: Participants will receive a single dose of RO7121932 administered as IV infusion.